aav2-rep1
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02553135)
Timeline
Indications
Studied for
Mechanism of action
- Alanine aminotransferaseSUBSTRATE
GPT substrate
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav2-rep1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03496012 | Phase 3 | Dec 11, 2017 | NightstaRx Limited |
| NCT03507686 | Phase 2 | Nov 6, 2017 | NightstaRx Limited |
| NCT02553135 | Phase 2 | Sep 1, 2015 | University of Miami |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NightstaRx Limited | For profit | 2 | 2 | 2 | 2017 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1